Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation

References

• Johnson GL. ERK1/ERK2 MAPK Pathway. (Connections Map in the Database of Cell Signaling, as seen 27 February 2014), http://stke.sciencemag.org/cgi/cm/stkecm;CMP_10705. Sci Signal 2005
   Google Scholar
• Johnson GL. JNK MAPK Pathway. (Connections Map in the Database of Cell Signaling, as seen 27 February 2014)http://stke.sciencemag.org/cgi/cm/stkecm;CMP_10827. Sci Signal 2003
   Google Scholar
• Gary L. Johnson. p38 MAPK Pathway. (Connections Map in the Database of Cell Signaling, as seen 27 February 2014), http://stke.sciencemag.org/cgi/cm/stkecm;CMP_10958. Sci Signal 2008
   Google Scholar
• Zhou G, Bao ZQ, Dixon JE. Components of a new human protein kinase signal transduction pathway. J Biol Chem 1995; 270:12665-9; PMID:7759517; http://dx.doi.org/10.1074/jbc.270.21.12665
   PubMed Web of Science ®Google Scholar
• Lee JD, Ulevitch RJ, Han J. Primary structure of BMK1: a new mammalian map kinase. Biochem Biophys Res Commun 1995; 213:715-24; PMID:7646528; http://dx.doi.org/10.1006/bbrc.1995.2189
   PubMed Web of Science ®Google Scholar
• Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 2006; 24:21-44; PMID:16393692; http://dx.doi.org/10.1080/02699050500284218
   PubMed Web of Science ®Google Scholar
• Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26:3291-310; PMID:17496923; http://dx.doi.org/10.1038/sj.onc.1210422
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363:809-19; PMID:20818844; http://dx.doi.org/10.1056/NEJMoa1002011
   PubMed Web of Science ®Google Scholar
• Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, Kulkarni SG, Rominger CM, Erskine S, Fisher KE, Yang J, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 2011; 17:989-1000; PMID:21245089; http://dx.doi.org/10.1158/1078-0432.CCR-10-2200
   PubMed Web of Science ®Google Scholar
• Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, Cockerill M, Cartlidge S, Smith PD. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 2007; 6:2209-19; PMID:17699718; http://dx.doi.org/10.1158/1535-7163.MCT-07-0231
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S, Malaponte G, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget 2012; 3:1068-111; PMID:23085539; http://dx.doi.org/10.18632/oncotarget.659
   PubMed Web of Science ®Google Scholar
• Little AS, Smith PD, Cook SJ. Mechanisms of acquired resistance to ERK1/2 pathway inhibitors. Oncogene 2013; 32:1207-15; PMID:22562245; http://dx.doi.org/10.1038/onc.2012.160.
   PubMed Web of Science ®Google Scholar
• Kato Y, Tapping RI, Huang S, Watson MH, Ulevitch RJ, Lee JD. Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature 1998; 395:713-6; PMID:9790194; http://dx.doi.org/10.1038/27234
   PubMed Web of Science ®Google Scholar
• Esparis-Ogando A, Diaz-Rodriguez E, Montero JC, Yuste L, Crespo P, Pandiella A. Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2. Mol Cell Biol 2002; 22:270-85; PMID:11739740; http://dx.doi.org/10.1128/MCB.22.1.270-285.2002
   PubMed Web of Science ®Google Scholar
• English JM, Pearson G, Hockenberry T, Shivakumar L, White MA, Cobb MH. Contribution of the ERK5/MEK5 pathway to Ras/Raf signaling and growth control. J Biol Chem 1999; 274:31588-92; PMID:10531364; http://dx.doi.org/10.1074/jbc.274.44.31588
   PubMed Web of Science ®Google Scholar
• Kamakura S, Moriguchi T, Nishida E. Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J Biol Chem 1999; 274:26563-71; PMID:10473620; http://dx.doi.org/10.1074/jbc.274.37.26563
   PubMed Web of Science ®Google Scholar
• Mody N, Leitch J, Armstrong C, Dixon J, Cohen P. Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway. FEBS Lett 2001; 502:21-4; PMID:11478941; http://dx.doi.org/10.1016/S0014-5793(01)02651-5
   PubMed Web of Science ®Google Scholar
• Squires MS, Nixon PM, Cook SJ. Cell-cycle arrest by PD184352 requires inhibition of extracellular signal-regulated kinases (ERK) 1/2 but not ERK5/BMK1. Biochem J 2002; 366:673-80; PMID:12069688; http://dx.doi.org/10.1042/bj20020372
   PubMed Web of Science ®Google Scholar
• Ortiz-Ruiz MJ, Alvarez-Fernandez S, Parrott T, Zaknoen S, Burrows FJ, Ocana A, Pandiella A, Esparis-Ogando A. Therapeutic potential of ERK5 targeting in triple negative breast cancer. Oncotarget 2014; 5:11308-18; PMID:25350956; http://dx.doi.org/10.18632/oncotarget.2324
   PubMed Web of Science ®Google Scholar
• Montero JC, Ocana A, Abad M, Ortiz-Ruiz MJ, Pandiella A, Esparis-Ogando A. Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target. PLoS One 2009; 4:e5565; PMID:19440538; http://dx.doi.org/10.1371/journal.pone.0005565
   PubMed Web of Science ®Google Scholar
• Mehta PB, Jenkins BL, McCarthy L, Thilak L, Robson CN, Neal DE, Leung HY. MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene 2003; 22:1381-9; PMID:12618764; http://dx.doi.org/10.1038/sj.onc.1206154
   PubMed Web of Science ®Google Scholar
• Zen K, Yasui K, Nakajima T, Zen Y, Gen Y, Mitsuyoshi H, Minami M, Mitsufuji S, Tanaka S, Itoh Y, et al. ERK5 is a target for gene amplification at 17p11 and promotes cell growth in hepatocellular carcinoma by regulating mitotic entry. Genes Chromosomes Cancer 2009; 48:109-20; PMID:18973138; http://dx.doi.org/10.1002/gcc.20624
   PubMed Web of Science ®Google Scholar
• Weston CR, Balmanno K, Chalmers C, Hadfield K, Molton SA, Ley R, Wagner EF, Cook SJ. Activation of ERK1/2 by deltaRaf-1:ER* represses Bim expression independently of the JNK or PI3K pathways. Oncogene 2003; 22:1281-93; PMID:12618753; http://dx.doi.org/10.1038/sj.onc.1206261
   PubMed Web of Science ®Google Scholar
• Allen LF, Sebolt-Leopold J, Meyer MB. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol 2003; 30:105-16; PMID:14613031; http://dx.doi.org/10.1053/j.seminoncol.2003.08.012
   PubMed Web of Science ®Google Scholar
• Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010; 140:209-21; PMID:20141835; http://dx.doi.org/10.1016/j.cell.2009.12.040
   PubMed Web of Science ®Google Scholar
• Gilley R, March HN, Cook SJ. ERK1/2, but not ERK5, is necessary and sufficient for phosphorylation and activation of c-Fos. Cell Signal 2009; 21:969-77; PMID:19249353; http://dx.doi.org/10.1016/j.cellsig.2009.02.006
   PubMed Web of Science ®Google Scholar
• Carvajal-Vergara X, Tabera S, Montero JC, Esparis-Ogando A, Lopez-Perez R, Mateo G, Gutierrez N, Parmo-Cabanas M, Teixido J, San Miguel JF, et al. Multifunctional role of Erk5 in multiple myeloma. Blood 2005; 105:4492-9; PMID:15692064; http://dx.doi.org/10.1182/blood-2004-08-2985
   PubMed Web of Science ®Google Scholar
• Yang Q, Deng X, Lu B, Cameron M, Fearns C, Patricelli MP, Yates JR, 3rd, Gray NS, Lee JD. Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell 2010; 18:258-67; PMID:20832753; http://dx.doi.org/10.1016/j.ccr.2010.08.008
   PubMed Web of Science ®Google Scholar
• Tatake RJ, O'Neill MM, Kennedy CA, Wayne AL, Jakes S, Wu D, Kugler SZ, Jr., Kashem MA, Kaplita P, Snow RJ. Identification of pharmacological inhibitors of the MEK5/ERK5 pathway. Biochem Biophys Res Commun 2008; 377:120-5; PMID:18834865; http://dx.doi.org/10.1016/j.bbrc.2008.09.087
   PubMed Web of Science ®Google Scholar
• Gilley R, Lochhead PA, Balmanno K, Oxley D, Clark J, Cook SJ. CDK1, not ERK1/2 or ERK5, is required for mitotic phosphorylation of BIMEL. Cell Signal 2012; 24:170-80; PMID:21924351; http://dx.doi.org/10.1016/j.cellsig.2011.08.018
   PubMed Web of Science ®Google Scholar
• Balmanno K, Chell SD, Gillings AS, Hayat S, Cook SJ. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Int J Cancer 2009; 125:2332-41; PMID:19637312; http://dx.doi.org/10.1002/ijc.24604
   PubMed Web of Science ®Google Scholar
• Gavine PR, Wang M, Yu D, Hu E, Huang C, Xia J, Su X, Fan J, Zhang T, Ye Q, et al. Identification and validation of dysregulated MAPK7 (ERK5) as a novel oncogenic target in squamous cell lung and oesophageal carcinoma. AACR Annual Meeting 2014: Abstract 2923 2014
   Google Scholar
• Drew BA, Burow ME, Beckman BS. MEK5/ERK5 pathway: the first fifteen years. Biochim Biophys Acta 2012; 1825:37-48; PMID:22020294
   PubMed Web of Science ®Google Scholar
• Lochhead PA, Gilley R, Cook SJ. ERK5 and its role in tumour development. Biochem Soc Trans 2012; 40:251-6; PMID:22260700; http://dx.doi.org/10.1042/BST20110663
   PubMed Web of Science ®Google Scholar
• Nithianandarajah-Jones GN, Wilm B, Goldring CE, Muller J, Cross MJ. ERK5: structure, regulation and function. Cell Signal 2012; 24:2187-96; PMID:22800864; http://dx.doi.org/10.1016/j.cellsig.2012.07.007.
   PubMed Web of Science ®Google Scholar
• Yang Q, Lee JD. Targeting the BMK1 MAP kinase pathway in cancer therapy. Clin Cancer Res 2011; 17:3527-32; PMID:21385929; http://dx.doi.org/10.1158/1078-0432.CCR-10-2504
   PubMed Web of Science ®Google Scholar
• Deng X, Elkins JM, Zhang J, Yang Q, Erazo T, Gomez N, Choi HG, Wang J, Dzamko N, Lee JD, et al. Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones. Eur J Med Chem 2013; 70:758-67; PMID:24239623; http://dx.doi.org/10.1016/j.ejmech.2013.10.052
   PubMed Web of Science ®Google Scholar
• Deng X, Yang Q, Kwiatkowski N, Sim T, McDermott U, Settleman JE, Lee JD, Gray NS. Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a Potent and Selective Inhibitor of Big MAP Kinase 1. ACS Med Chem Lett 2011; 2:195-200; PMID:21412406; http://dx.doi.org/10.1021/ml100304b
   PubMed Web of Science ®Google Scholar
• Elkins JM, Wang J, Deng X, Pattison MJ, Arthur JS, Erazo T, Gomez N, Lizcano JM, Gray NS, Knapp S. X-ray crystal structure of ERK5 (MAPK7) in complex with a specific inhibitor. J Med Chem 2013; 56:4413-21; PMID:23656407; http://dx.doi.org/10.1021/jm4000837
   PubMed Web of Science ®Google Scholar
• English JM, Pearson G, Baer R, Cobb MH. Identification of substrates and regulators of the mitogen-activated protein kinase ERK5 using chimeric protein kinases. J Biol Chem 1998; 273:3854-60; PMID:9461566; http://dx.doi.org/10.1074/jbc.273.7.3854
   PubMed Web of Science ®Google Scholar
• Chiariello M, Marinissen MJ, Gutkind JS. Multiple mitogen-activated protein kinase signaling pathways connect the cot oncoprotein to the c-jun promoter and to cellular transformation. Mol Cell Biol 2000; 20:1747-58; PMID:10669751; http://dx.doi.org/10.1128/MCB.20.5.1747-1758.2000
   PubMed Web of Science ®Google Scholar
• Abe J, Takahashi M, Ishida M, Lee JD, Berk BC. c-Src is required for oxidative stress-mediated activation of big mitogen-activated protein kinase 1. J Biol Chem 1997; 272:20389-94; PMID:9252345; h`ttp://dx.doi.org/10.1074/jbc.272.33.20389
   PubMed Web of Science ®Google Scholar
• Barros JC, Marshall CJ. Activation of either ERK1/2 or ERK5 MAP kinase pathways can lead to disruption of the actin cytoskeleton. J Cell Sci 2005; 118:1663-71; PMID:15797923; http://dx.doi.org/10.1242/jcs.02308
   PubMed Web of Science ®Google Scholar
• Schramp M, Ying O, Kim TY, Martin GS. ERK5 promotes Src-induced podosome formation by limiting Rho activation. J Cell Biol 2008; 181:1195-210; PMID:18573916; http://dx.doi.org/10.1083/jcb.200801078
   PubMed Web of Science ®Google Scholar
• Gangarosa LM, Sizemore N, Graves-Deal R, Oldham SM, Der CJ, Coffey RJ. A raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of rat intestinal epithelial cells. J Biol Chem 1997; 272:18926-31; PMID:9228072; http://dx.doi.org/10.1074/jbc.272.30.18926
   PubMed Web of Science ®Google Scholar
• McCarthy SA, Samuels ML, Pritchard CA, Abraham JA, McMahon M. Rapid induction of heparin-binding epidermal growth factor/diphtheria toxin receptor expression by Raf and Ras oncogenes. Genes Dev 1995; 9:1953-64; PMID:7649477; http://dx.doi.org/10.1101/gad.9.16.1953
   PubMed Web of Science ®Google Scholar
• Schulze A, Nicke B, Warne PH, Tomlinson S, Downward J. The transcriptional response to Raf activation is almost completely dependent on Mitogen-activated Protein Kinase Kinase activity and shows a major autocrine component. Mol Biol Cell 2004; 15:3450-63; PMID:15090615; http://dx.doi.org/10.1091/mbc.E03-11-0807
   PubMed Web of Science ®Google Scholar
• Schulze A, Lehmann K, Jefferies HB, McMahon M, Downward J. Analysis of the transcriptional program induced by Raf in epithelial cells. Genes Dev 2001; 15:981-94; PMID:11316792; http://dx.doi.org/10.1101/gad.191101
   PubMed Web of Science ®Google Scholar
• Mulloy R, Salinas S, Philips A, Hipskind RA. Activation of cyclin D1 expression by the ERK5 cascade. Oncogene 2003; 22:5387-98; PMID:12934098; http://dx.doi.org/10.1038/sj.onc.1206839
   PubMed Web of Science ®Google Scholar
• Smalley KS, Lioni M, Dalla Palma M, Xiao M, Desai B, Egyhazi S, Hansson J, Wu H, King AJ, Van Belle P, et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther 2008; 7:2876-83; PMID:18790768; http://dx.doi.org/10.1158/1535-7163.MCT-08-0431
   PubMed Web of Science ®Google Scholar
• Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 2004; 102:37-46; PMID:15056497; http://dx.doi.org/10.1016/j.pharmthera.2004.01.002
   PubMed Web of Science ®Google Scholar
• Goh KC, Novotny-Diermayr V, Hart S, Ong LC, Loh YK, Cheong A, Tan YC, Hu C, Jayaraman R, William AD, et al. TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties. Leukemia 2012; 26:236-43; PMID:21860433; http://dx.doi.org/10.1038/leu.2011.218
   PubMed Web of Science ®Google Scholar
• Vinci M, Gowan S, Boxall F, Patterson L, Zimmermann M, Court W, Lomas C, Mendiola M, Hardisson D, Eccles SA. Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol 2012; 10:29; PMID:22439642; http://dx.doi.org/10.1186/1741-7007-10-29
   PubMed Web of Science ®Google Scholar
• Balmanno K, Cook SJ. Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells. Oncogene 1999; 18:3085-97; PMID:10340380; http://dx.doi.org/10.1038/sj.onc.1202647
   PubMed Web of Science ®Google Scholar
• Garner AP, Weston CR, Todd DE, Balmanno K, Cook SJ. Delta MEKK3:ER* activation induces a p38 α/β 2-dependent cell cycle arrest at the G2 checkpoint. Oncogene 2002; 21:8089-104; PMID:12444545; http://dx.doi.org/10.1038/sj.onc.1206000
   PubMed Web of Science ®Google Scholar
• Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82:1107-12; PMID:2359136; http://dx.doi.org/10.1093/jnci/82.13.1107
   PubMed Web of Science ®Google Scholar
• Willmore E, Elliott SL, Mainou-Fowler T, Summerfield GP, Jackson GH, O'Neill F, Lowe C, Carter A, Harris R, Pettitt AR, et al. DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia. Clin Cancer Res 2008; 14:3984-92; PMID:18559621; http://dx.doi.org/10.1158/1078-0432.CCR-07-5158
   PubMed Web of Science ®Google Scholar
• Roberts OL, Holmes K, Muller J, Cross DA, Cross MJ. ERK5 is required for VEGF-mediated survival and tubular morphogenesis of primary human microvascular endothelial cells. J Cell Sci 2010; 123:3189-200; PMID:20736307; http://dx.doi.org/10.1242/jcs.072801
   PubMed Web of Science ®Google Scholar